Recent studies have evidenced that KRAS-driven lung and pancreatic cancer with KEAP1 or NRF2 mutations are highly dependent on glutaminolysis and are vulnerable to glutaminase inhibition32,61. This evidence concerns the gene GLS and familial pancreatic carcinoma.